Rapport Therapeutics (RAPP) closed at $23.16 on November 20, 2026, down 1.8% from the previous close, on volume of 405,093 shares (30-day average 1,185,306).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 22, 2026 | Put Spread | 20-Nov-2620 : 32.5 P | 1,948 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
RAPP rallies as Rapport prices $175M stock deal and sets $26.78 convertible conversion price
Market Chameleon (Thu, 29-Oct 7:44 AM ET)
Globe Newswire (Wed, 28-Oct 6:00 AM ET)
Globe Newswire (Tue, 27-Oct 4:32 PM ET)
Market Chameleon (Wed, 21-Oct 6:39 AM ET)
Rapport’s RAP-219 posts statistically significant Week 3 mania improvements in Phase 2 bipolar trial
Market Chameleon (Tue, 20-Oct 3:06 AM ET)
Globe Newswire (Tue, 20-Oct 6:00 AM ET)
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.
As of November 20, 2026, RAPP stock price declined to $23.16 with 405,093 million shares trading.
RAPP has a beta of 1.62, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.25 to the broad based SPY ETF.
RAPP has a market cap of $1.37 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
RAPP has underperformed the market in the last year with a return of -13.7%, while the SPY ETF gained +6.9%. In the last 3 month period, RAPP fell short of the market, returning -51.6%, while SPY returned -9.3%. However, in the most recent 2 weeks RAPP has outperformed the stock market by returning -5.2%, while SPY returned -6.2%.
RAPP support price is $22.41 and resistance is $24.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.